September 11 (Reuters) – American hospitals tax nearly a third of their allocated supply of COVID-19 drug remediesvir since July, according to unpublished government data provided to Reuters by a group of American pharmacists. Have given.
Some hospitals said that they are still buying Gilead Sciences medicine to make inventory. But he said the current supply is adequate, in part because they are limiting the use of critically ill patients.
The Food and Drug Administration has allowed more lenient remasivir use, but 6 of the 8 major hospital systems contacted by Reuters said they were not using it for liberal cases.
The recession shows that the drug shortage is over and attempts by Gilead to use Remedisvir threaten it, which sells it under the brand name Vecleri in some countries.
The US Department of Health and Human Services (HHS) on Friday told hospitals and other healthcare organizations that between July 6 and September 8, state and territory public health systems offered approximately 72% of remediesvir, which was called Michael Gannio, The senior director acknowledged pharmacy practice and quality of the American Society of Health-System Pharmacists, told Reuters.
He said that hospitals accepted only two-thirds of states and territories. It was not immediately clear what happened to the surplus supply.
Neither Gilead nor HHS responded immediately to a request for comment.
The surplus of Remedivir – which costs $ 3,120 for a 6-vial intravenous course – is already a change in the epidemic, when the drug supply was reduced in some areas.
The government-led distribution of Remedisvir will end in late September. Hospitals said they had little information about availability.
Remdesivir was first authorized by the FDA in May, with COVID-19 patients hospitalized for emergency use, and after data showed support for oxygen showed that it helped improve the hospital.
The agency last month expanded access to hospitalized patients who do not require oxygen support based on data published in the JAMA Medical Journal, indicating that the drug provides modest benefits for those patients.
The new data has left many experts unaffiliated.
The head of infectious diseases services at Emory University Hospital in Atlanta, Drs. Aneesh Mehta said that Emory is focusing supply on the patients most likely to benefit.
“I’m not too impressed with the study,” said Dr. Cleveland, an infectious disease specialist at the Cleveland Clinic. Adarsh Bhimraj said. He said he remains “skeptical” about using Remedisvir in patients with moderate COVID, especially given its price. (Reporting by Dena Beazley; Editing by Peter Henderson and Bill Burcott)